Top

BMC Cardiovascular Disorders

Published in:

Open Access 01-12-2021 | Pulmonary Hypertension | Research

The role of matrix metalloproteinases in patients with pulmonary hypertension: data from a prospective study

Authors: Adriana Marc, Calin Pop, Adela-Viviana Sitar-Taut, Liviuta Budisan, Ioana Berindan-Neagoe, Dana Pop

Published in: BMC Cardiovascular Disorders | Issue 1/2021

Abstract

Background

Despite several therapies, pulmonary hypertension (PH) is still a severe disease which can lead to right heart failure. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) are involved in cardiac and vascular remodeling in PH. Therefore, these biomarkers play an important role in PH patients. This study investigated whether TIMP-4, MMP-2, and N-terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) plasma levels are useful in assessing the severity of PH and other clinical or echocardiographic parameters.

Methods

The concentrations of MMP-2, TIMP-4, and NT-proBNP in 68 PH patients were compared with those of 12 controls without PH. All patients underwent a physical examination, echocardiography, and were checked for the presence of cardiovascular risk factors; also, plasma concentrations of MMP-2, TIMP-4, NT-proBNP, total cholesterol, and triglycerides were determined.

Results

In PH patients, significantly elevated plasma levels of TIMP-4 (PH: 2877.99 ± 1363.78 pg/ml, control: 2028.38 ± 762.67 pg/ml, p = 0.0068) and NT-proBNP ( PH: 2405.00 pg/ml—5423.47 ± 6703.38 pg/ml, control: 411.0000 pg/ml—421.75 ± 315.37 pg/ml, p = 0.01) were detected. We also observed that MMP-2 and NT-proBNP were significantly increased in patients with higher WHO functional class (p = 0.001 for MMP-2, p = 0.008 for NT-proBNP), higher pressure in the pulmonary artery (p = 0.002 for MMP-2, p = 0.001 for NT-proBNP), and more severe tricuspid regurgitation (p = 0.001 for MMP-2, p = 0.009 for NT-proBNP). TIMP-4 was elevated in patients with more severe pressure in the pulmonary artery (p = 0.006).

Conclusions

The plasma levels of TIMP-4 and NT-proBNP are higher in PH patients. MMP-2 and NT-proBNP correlates with different PH parameters severity (WHO functional class, sPAP severity, TV regurgitation severity). Therefore, plasmatic levels of MMP-2 and NT-proBNP at this kind of patients reflect disease severity and may have a prognostic role. MMP-2 can help assess the beneficial effects of PH pharmacotherapy on tissue remodeling. These remodeling biomarkers may not have a diagnostic value but they have the potential to predict survival. Nevertheless, a greater understanding of the involvement of MMPs in PH is mandatory to further explore the prognostic role and the possibilities of therapeutic MMP inhibition in PH.

Konstam MA, Kiernan MS, Bernstein D, Bozkurt B, Jacob M, Kapur NK, Kociol RD, Lewis EF, Mehra MR, Pagani FD, Raval AN, Ward C. Evaluation and management of right-sided heart failure: a scientific statement from the american heart association. Circulation. 2018;137:e578–622. https://doi.org/10.1161/CIR.0000000000000560.CrossRefPubMed

Chelladurai P, Seeger W, Pullamsetti SS. Matrix metalloproteinases and their inhibitors in pulmonary hypertension. Eur Respir J. 2012;40:766–82. https://doi.org/10.1183/09031936.00209911.CrossRefPubMed

Badesch DB, Champion HC, Gomez Sanchez MA, Hoeper MM, Loyd JE, Manes A, McGoon M, Naeije R, Olschewski H, Oudiz RJ, Torbicki A. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54:S55–66. https://doi.org/10.1016/j.jacc.2009.04.011.CrossRefPubMed

Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M; ESC Scientific Document Group. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67–119. https://doi.org/10.1093/eurheartj/ehv317.

Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, Gomez Sanchez MA, Krishna Kumar R, Landzberg M, Machado RF, Olschewski H, Robbins IM, Souza R. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013;62:D34-41. https://doi.org/10.1016/j.jacc.2013.10.029.CrossRefPubMed

Stenmark KR, Meyrick B, Galie N, Mooi WJ, McMurtry IF. Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol. 2009;297:L1013–32. https://doi.org/10.1152/ajplung.00217.2009.CrossRefPubMed

Jones PL, Cowan KN, Rabinovitch M. Tenascin-C, proliferation and subendothelial fibronectin in progressive pulmonary vascular disease. Am J Pathol. 1997;150:1349–60.PubMedPubMedCentral

Meyrick B. Structure function correlates in the pulmonary vasculature during acute lung injury and chronic pulmonary hypertension. Toxicol Pathol. 1991;19:447–57. https://doi.org/10.1177/0192623391019004-113.CrossRefPubMed

Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res. 2003;92:827–39. https://doi.org/10.1161/01.RES.0000070112.80711.3D.CrossRefPubMed

10.

Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006;69:562–73. https://doi.org/10.1016/j.cardiores.2005.12.002.CrossRefPubMed

11.

Matsui K, Takano Y, Yu ZX, Hi JE, Stetler-Stevenson WG, Travis WD, Ferrans VJ. Immunohistochemical study of endothelin-1 and matrix metalloproteinases in plexogenic pulmonary arteriopathy. Pathol Res Pract. 2002;198:403–12. https://doi.org/10.1078/0344-0338-00273.CrossRefPubMed

12.

Lepetit H, Eddahibi S, Fadel E, Frisdal E, Munaut C, Noel A, Humbert M, Adnot S, D’Ortho MP, Lafuma C. Smooth muscle cell matrix metalloproteinases in idiopathic pulmonary arterial hypertension. Eur Respir J. 2005;25:834–42. https://doi.org/10.1183/09031936.05.00072504.CrossRefPubMed

13.

Ricou B, Nicod L, Lacraz S, Welgus HG, Suter PM, Dayer JM. Matrix metalloproteinases and TIMP in acute respiratory distress syndrome. Am J Respir Crit Care Med. 1996;154:346–52. https://doi.org/10.1164/ajrccm.154.2.8756805.CrossRefPubMed

14.

Tiede SL, Wassenberg M, Christ K, Schermuly RT, Seeger W, Grimminger F, Ghofrani HA, Gall H. Biomarkers of tissue remodeling predict survival in patients with pulmonary hypertension. Int J Cardiol. 2016;223:821–6. https://doi.org/10.1016/j.ijcard.2016.08.240.CrossRefPubMed

15.

Schumann C, Lepper PM, Frank H, Schneiderbauer R, Wibmer T, Kropf C, Stoiber KM, Rüdiger S, Kruska L, Krahn T, Kramer F. Circulating biomarkers of tissue remodelling in pulmonary hypertension. Biomarkers. 2010;15:523–32. https://doi.org/10.3109/1354750X.2010.492431.CrossRefPubMed

16.

Steeds RP, Garbi M, Cardim N, Kasprzak JD, Sade E, Nihoyannopoulos P, Popescu BA, Stefanidis A, Cosyns B, Monaghan M, Aakhus S, Edvardsen T, Flachskampf F, Galiuto L, Athanassopoulos G, Lancellotti P, Delgado V, Donal E, Galderisi M, Lombardi M, Muraru D, Haugaa K. EACVI appropriateness criteria for the use of transthoracic echocardiography in adults: a report of literature and current practice review. Eur Heart J Cardiovasc Imaging. 2017;18:1191–204. https://doi.org/10.1093/ehjci/jew333.CrossRefPubMed

17.

Patel MI, Melrose J, Ghosh P, Appleberg M. Increased synthesis of matrix metalloproteinases by aortic smooth muscle cells is implicated in the etiopathogenesis of abdominal aortic aneurysms. J Vasc Surg. 1996;24:82–92. https://doi.org/10.1016/s0741-5214(96)70148-9.CrossRefPubMed

18.

Kramer F, Sandner P, Klein M, Krahn T. Plasma concentrations of matrix metalloproteinase-2, tissue inhibitor of metalloproteinase-1 and osteopontin reflect severity of heart failure in DOCA-salt hypertensive rat. Biomarkers. 2008;13:270–81. https://doi.org/10.1080/13547500801903123.CrossRefPubMed

19.

Greene J, Wang M, Liu YE, Raymond LA, Rosen C, Shi YE. Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4. J Biol Chem. 1996;271:30375–80. https://doi.org/10.1074/jbc.271.48.30375.CrossRefPubMed

20.

Luchner A, Stevens TL, Borgeson DD, Redfield M, Wei CM, Porter JG, Burnett JC. Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure. Am J Physiol. 1998;274:H1684–9. https://doi.org/10.1152/ajpheart.1998.274.5.H1684.CrossRefPubMed

21.

Luchner A, Muders F, Dietl O, Friedrich E, Blumberg F, Protter AA, Riegger GA, Elsner D. Differential expression of cardiac ANP and BNP in a rabbit model of progressive left ventricular dysfunction. Cardiovasc Res. 2001;51:601–7. https://doi.org/10.1016/s0008-6363(01)00316-9.CrossRefPubMed

22.

Eimer MJ, Ekery DL, Rigolin VH, Bonow RO, Carnethon MR, Cotts WG. Elevated B-type natriuretic peptide in asymptomatic men with chronic aortic regurgitation and preserved left ventricular systolic function. Am J Cardiol. 2004;94:676–8. https://doi.org/10.1016/j.amjcard.2004.05.043.CrossRefPubMed

23.

Burke MA, Cotts WG. Interpretation of B-type natriuretic peptide in cardiac disease and other comorbid conditions. Heart Fail Rev. 2007;12:23–36. https://doi.org/10.1007/s10741-007-9002-9.CrossRefPubMed

24.

Detaint D, Messika-Zeitoun D, Avierinos JF, Scott C, Chen H, Burnett JC, Enriquez-Sarano M. B-type natriuretic peptide in organic mitral regurgitation: determinants and impact on outcome. Circulation. 2005;111:2391–7. https://doi.org/10.1161/01.CIR.0000164269.80908.9D.CrossRefPubMed

25.

Arat-Ozkan A, Kaya A, Yigit Z, Balci H, Okçün B, Yazicioglu N, Küçükoglu S. Serum N-terminal pro-BNP levels correlate with symptoms and echocardiographic findings in patients with mitral stenosis. Echocardiography. 2005;22:473–8. https://doi.org/10.1111/j.1540-8175.2005.04085.x.CrossRefPubMed

26.

McCullough PA, Hollander JE, Nowak RM, Storrow AB, Duc P, Omland T, McCord J, Herrmann HC, Steg PG, Westheim A, Knudsen CW, Abraham WT, Lamba S, Wu AH, Perez A, Clopton P, Krishnaswamy P, Kazanegra R, Maisel AS. Uncovering heart failure in patients with a history of pulmonary disease: rationale for the early use of B-type natriuretic peptide in the emergency department. Acad Emerg Med. 2003;10:198–204. https://doi.org/10.1111/j.1553-2712.2003.tb01990.x.CrossRefPubMed

27.

Koo HS, Kim KC, Hong YM. Gene expressions of nitric oxide synthase and matrix metalloproteinase-2 in monocrotaline-induced pulmonary hypertension in rats after bosentan treatment. Korean Circ J. 2011;41:83–90. https://doi.org/10.4070/kcj.2011.41.2.83.CrossRefPubMedPubMedCentral

28.

Atlı Ö, Ilgın S, Ergun B, Burukoğlu D, Musmul A, Sırmagül B. Matrix metalloproteinases are possible targets in monocrotaline-induced pulmonary hypertension: investigation of anti-remodeling effects of alagebrium and everolimus. Anatol J Cardiol. 2017;17:8–17. https://doi.org/10.14744/AnatolJCardiol.2016.6891.CrossRefPubMed

29.

Tayebjee MH, Nadar S, Blann AD, Gareth Beevers D, MacFadyen RJ, Lip GY. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Am J Hypertens. 2004;17:764–9. https://doi.org/10.1016/j.amjhyper.2004.05.019.CrossRefPubMed

30.

Mawatari E, Hongo M, Sakai A, Terasawa F, Takahashi M, Yazaki Y, Kinoshita O, Ikeda U. Amlodipine prevents monocrotaline-induced pulmonary arterial hypertension and prolongs survival in rats independent of blood pressure lowering. Clin Exp Pharmacol Physiol. 2007;34:594–600. https://doi.org/10.1111/j.1440-1681.2007.04618.x.CrossRefPubMed

31.

Schäfer M, Ivy DD, Nguyen K, Boncella K, Frank BS, Morgan GJ, Miller-Reed K, Truong U, Colvin K, Yeager ME. Metalloproteinases and their inhibitors are associated with pulmonary arterial stiffness and ventricular function in pediatric pulmonary hypertension. Am J Physiol Heart Circ Physiol. 2021;321:H242–52. https://doi.org/10.1152/ajpheart.00750.2020.CrossRefPubMed

32.

Yap LB, Mukerjee D, Timms PM, Ashrafian H, Coghlan JG. Natriuretic peptides, respiratory disease, and the right heart. Chest. 2004;126:1330–6. https://doi.org/10.1378/chest.126.4.1330.CrossRefPubMed

33.

Leuchte HH, Baumgartner RA, Nounou ME, Vogeser M, Neurohr C, Trautnitz M, Behr J. Brain natriuretic peptide is a prognostic parameter in chronic lung disease. Am J Respir Crit Care Med. 2006;173:744–50. https://doi.org/10.1164/rccm.200510-1545OC.CrossRefPubMed

34.

Pieralli F, Olivotto I, Vanni S, Conti A, Camaiti A, Targioni G, Grifoni S, Berni G. Usefulness of bedside testing for brain natriuretic peptide to identify right ventricular dysfunction and outcome in normotensive patients with acute pulmonary embolism. Am J Cardiol. 2006;97:1386–90. https://doi.org/10.1016/j.amjcard.2005.11.075.CrossRefPubMed

35.

Krüger S, Graf J, Merx MW, Koch KC, Kunz D, Hanrath P, Janssens U. Brain natriuretic peptide predicts right heart failure in patients with acute pulmonary embolism. Am Heart J. 2004;147:60–5. https://doi.org/10.1016/s0002-8703(03)00528-3.CrossRefPubMed

36.

Nagaya N, Nishikimi T, Okano Y, Uematsu M, Satoh T, Kyotani S, Kuribayashi S, Hamada S, Kakishita M, Nakanishi N, Takamiya M, Kunieda T, Matsuo H, Kangawa K. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol. 1998;31:202–8. https://doi.org/10.1016/s0735-1097(97)00452-x.CrossRefPubMed

37.

He J, Fang W, Lv B, He JG, Xiong CM, Liu ZH, He ZX. Diagnosis of chronic thromboembolic pulmonary hypertension: comparison of ventilation/perfusion scanning and multidetector computed tomography pulmonary angiography with pulmonary angiography. Nucl Med Commun. 2012;33:459–63. https://doi.org/10.1097/MNM.0b013e32835085d9.CrossRefPubMed

38.

Brugger N, Lichtblau M, Maeder MT, Müller H, Pellaton C, Yerly P. Two-dimensional transthoracic echocardiography at rest for the diagnosis, screening and management of pulmonary hypertension. Swiss Med Wkly. 2021;151: w20486. https://doi.org/10.4414/smw.2021.20486.CrossRefPubMed

Title: The role of matrix metalloproteinases in patients with pulmonary hypertension: data from a prospective study
Authors: Adriana Marc
Calin Pop
Adela-Viviana Sitar-Taut
Liviuta Budisan
Ioana Berindan-Neagoe
Dana Pop
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Pulmonary Hypertension
Heart Failure
Pulmonary Hypertension
Pulmonary Hypertension
Pulmonary Hypertension
Biomarkers
Published in: BMC Cardiovascular Disorders / Issue 1/2021
Electronic ISSN: 1471-2261
DOI: https://doi.org/10.1186/s12872-021-02424-5

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

At a glance: The STEP trials

Springer Medicine

The role of matrix metalloproteinases in patients with pulmonary hypertension: data from a prospective study

Abstract

Background

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Serum alanine aminotransferase activity and risk factors for cardiovascular disease in a Caucasian population: the Tromsø study

Takotsubo syndrome as an overlooked and elusive cause of a single episode of dyspnea in young women: a case report

Sex and age difference in risk factor distribution, trend, and long-term outcome of patients undergoing isolated coronary artery bypass graft surgery

Effects of empagliflozin in different phases of diabetes mellitus-related cardiomyopathy: a prospective observational study

Comprehensive analysis of autophagy-related genes and patterns of immune cell infiltration in valvular atrial fibrillation

Correction to: Multi‑modality biomarkers in the early prediction of ischaemic heart disease in middle‑aged men during a 21‑year follow‑up

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page